Study record · Zenagamtide

Once-daily oral zenagamtide in type 2 diabetes

HbA1c fell by about 0.9%, 1.3% and 1.4% across the three active dose groups, significantly more than placebo.

Key result

HbA1c fell by about 0.9%, 1.3% and 1.4% across the three active dose groups, significantly more than placebo.

Study designRandomized, double-blind, placebo-controlled dose-finding trial

PhasePhase II

PopulationAdults with type 2 diabetes on metformin with or without SGLT2 inhibitor

Sample size186

RouteOral

Regimen / exposure6, 25 or 50 mg once daily after escalation from 1.5 mg

Duration36 weeks + 4-week follow-up

ComparatorPlacebo

Primary endpoint / questionChange in HbA1c

Safety resultGI adverse events occurred in 26%, 41% and 47% across active groups versus 23% placebo; no deaths occurred.

Key limitationsPhase II and formulation-specific; oral and injectable regimens are not interchangeable.

Registry / identifierPMID 42532079 / NCT06542874